Table 1.
Patient characteristics in LCIG and orally treated patients.
Table 2.
Laboratory results in LCIG and orally treated patients.
Table 3.
Sensory and motor potentials from neurography in LCIG and orally treated patients.
Figure 1.
Correlation of daily levodopa dose and the number of neurographically impaired nerves.
The daily levodopa dose is indicated on the abscissa, the number of neurographically impaired nerves on the ordinate. Triangles and dots reflect the values of the orally treated and LCIG patients respectively. The regression line is provided for the data from the LCIG group for which the correlation coefficient (r) was significantly higher than in the orally treated group.
Table 4.
Correlations between the number of impaired nerves and patient parameters.